American Society of Hematology

Figure 1.

Figure 1. Survival of patients with r/r DLBCL treated with ibrutinib by COO subtype. (A) PFS (log-rank test, P = .85) and (B) OS (log-rank test, P = .97).

Survival of patients with r/r DLBCL treated with ibrutinib by COO subtype. (A) PFS (log-rank test, P = .85) and (B) OS (log-rank test, P = .97).

This Feature Is Available To Subscribers Only

Sign In or Create an Account